Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial

被引：0
|
作者：
Gluz, Oleg
Kreipe, Hans Heinrich
Christgen, Matthias
Degenhardt, Tom
Kates, Ronald E.
Liedtke, Cornelia
Shak, Steven
Clemens, Michael R.
Salem, Marwa
Markmann, Susanne
Liedtke, Bernd
Aktas, Bahriye
Henschen, Stephan
Pollmanns, Anke
Krabisch, Petra
Uleer, Christoph
Augustin, Doris
Thomssen, Christoph
Nitz, Ulrike
Harbeck, Nadia
机构：
[1] West German Study Grp, Monchengladbach, Germany
[2] Hannover Med Sch, Hannover, Germany
[3] Univ Hosp Munich, Cologne, Germany
[4] REK Consulting, Otterfing, Germany
[5] Univ Munster, D-48149 Munster, Germany
[6] Genom Hlth, Redwood City, CA USA
[7] Klinikum Mutterhaus, Trier, Germany
[8] Univ Clin Cologne, Cologne, Germany
[9] Univ Clin Rostock, Rostock, Germany
[10] Evangel Hosp, Bergisch Gladbach, Germany
[11] Univ Duisburg Essen, Dept Gynecol & Obstet, Essen, Germany
[12] Johanniter Clin Stendal, Stendal, Germany
[13] EKO, Oberhausen, Germany
[14] Klinikum Chemnitz, Dept Gynecol & Obstet, Chemnitz, Germany
[15] Klinikum Deggendorf, Deggendorf, Germany
[16] Univ Halle Wittenberg, D-06108 Halle, Germany
[17] Evangel Hosp Bethesda, Monchengladbach, Germany
[18] West German Study Grp, Munich, Germany
[19] Univ Munich, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
552
引用
收藏
页数：1
相关论文
共 21 条
  • [1] PROSPECTIVE COMPARISON OF RISK ASSESSMENT TOOLS IN EARLY BREAST CANCER: CORRELATION ANALYSIS FROM THE PHASE III WSG-PLAN B TRIAL
    Gluz, O.
    Kreipe, H. H.
    Degenhardt, T.
    Salem, M.
    Kates, R. E.
    Shak, S.
    Svedman, C.
    Liedtke, C.
    Nitz, U.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 18 - 18
  • [2] Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.
    Giuz, O.
    Kreipe, H.
    Degenhardt, T.
    Kates, R.
    Christgen, M.
    Liedtke, C.
    Shak, S.
    Clemens, M.
    Markmann, S.
    Uleer, C.
    Augustin, D.
    Thomssen, C.
    Nitz, U.
    Harbeck, N.
    CANCER RESEARCH, 2011, 71
  • [3] Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial
    Nitz, Ulrike
    Gluz, Oleg
    Kates, Ronald E.
    Hofmann, Daniel
    Kreipe, Hans H.
    Christgen, Matthias
    Shak, Steve
    Clemens, Michael
    Kraemer, Stefan
    Aktas, Bahriye
    Kuemmel, Sherko
    Reimer, Toralf
    Kusche, Manfred
    Heyl, Volker
    Lorenz-Salehi, Fatemah
    Just, Marianne
    Liedtke, Cornelia
    Wuerstlein, Rachel
    Harbeck, Nadia
    CANCER RESEARCH, 2015, 75
  • [4] Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis)
    Wuerstlein, R.
    Gluz, O.
    Kreipe, H.
    Kates, R.
    Degenhardt, T.
    Liedtke, C.
    Shak, S.
    Nitz, U.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S33 - S34
  • [5] Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial
    Gluz, O.
    Kreipe, H. H.
    Kates, R. E.
    Christgen, M.
    Liedtke, C.
    Shak, S.
    Clemens, M.
    Salem, M.
    Liedtke, B.
    Aktas, B.
    Markmann, S.
    Uleer, C.
    Augustin, D.
    Thomssen, C.
    Nitz, U.
    Harbeck, N.
    CANCER RESEARCH, 2012, 72
  • [6] Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score - Results from TransATAC.
    Cuzick, J.
    Dowsett, M.
    Wale, C.
    Salter, J.
    Quinn, E.
    Zabaglo, L.
    Howell, A.
    Buzdar, A.
    Forbes, J. F.
    CANCER RESEARCH, 2009, 69 (24) : 503S - 503S
  • [7] Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial
    Kolberg-Liedtke, Cornelia
    Oleg, Gluz
    Fred, Heinisch
    Friedrich, Feuerhake
    Hans, Kreipe
    Michael, Clemens
    Benno, Nuding
    Wolfram, Malter
    Toralf, Reimer
    Rachel, Wuerstlein
    Monika, Graeser
    Steve, Shak
    Ulrike, Nitz
    Ronald, Kates
    Matthias, Christgen
    Nadia, Harbeck
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [8] Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial
    Cornelia Kolberg-Liedtke
    Oleg Gluz
    Fred Heinisch
    Friedrich Feuerhake
    Hans Kreipe
    Michael Clemens
    Benno Nuding
    Wolfram Malter
    Toralf Reimer
    Rachel Wuerstlein
    Monika Graeser
    Steve Shak
    Ulrike Nitz
    Ronald Kates
    Matthias Christgen
    Nadia Harbeck
    Breast Cancer Research, 22
  • [9] PROSPECTIVE COMPARISON OF UPA/PAI-1, KI-67 BASED MOLECULAR CLASSIFICATION AND RECURRENCE SCORE IN HORMONE-RECEPTOR POSITIVE PRIMARY BREAST CANCER: PILOT PHASE OF THE RANDOMIZED WSG PLANB TRIAL
    Degenhardt, T.
    Gluz, O.
    Liedtke, C.
    Kreipe, H. H.
    Kates, R.
    Baehner, R.
    Bensman, E.
    Augustin, D.
    Nitz, U.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2011, 22 : 45 - 45
  • [10] PROGNOSTIC VALUE OF BREAST CANCER SUBTYPES BASED ON ER/PR, HER2 EXPRESSION AND KI-67 INDEX IN WOMEN RECEIVED ADJUVANT THERAPY AFTER CONSERVATIVE SURGERY FOR EARLY STAGES BREAST CANCER A RETROSPECTIVE CLINICAL STUDY
    Fouda, MennaAllah
    BREAST, 2018, 41 : S20 - S20
123